Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02982590|
Recruitment Status : Recruiting
First Posted : December 5, 2016
Last Update Posted : October 11, 2018
|Condition or disease||Intervention/treatment||Phase|
|Left Ventricular Thrombosis||Drug: Apixaban 5 MG Oral Tablet [ELIQUIS] Drug: Warfarin Sodium||Phase 3|
Current treatment for left ventricular thrombus is anti-coagulant or blood thinning agent known as warfarin. Recently at least three novel oral anticoagulant agents were used in the treatment of atrial fibrillation, pulmonary embolism and deep vein thrombosis (DVT).
Novel oral anticoagulant drugs will require no blood taking for INR monitoring, hence less visit and more convenience to patients. Latest studies also showed lesser rate of bleeding as compared to warfarin and hence relatively safer.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||December 2018|
Active Comparator: warfarin sodium
warfarin daily, dosage according to INR monitor. Aim INR 2-3
Drug: Warfarin Sodium
as controlled arm since warfarin is the standard therapy for LV thrombus
Other Name: Coumadin
Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.
Drug: Apixaban 5 MG Oral Tablet [ELIQUIS]
Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
Other Name: ELIQUIS
- Reduction of left ventricular thrombus size in cm2 (0 = total resolution) [ Time Frame: 3 months ]Reduction of left ventricular thrombus size in cm2 (0 = total resolution)
- Reduction of left ventricular thrombosis by more than 50% [ Time Frame: 3 months ]
- Evidence of clinically definite cardiac embolic ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by CT scan [ Time Frame: 3 months ]
- Life threatening bleeding attributed to the use of anti-coagulation [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02982590
|Contact: Dr W. Yus Haniff W. Isa, M.MEDemail@example.com|
|Contact: Dr Niny Hwong, MDfirstname.lastname@example.org|
|Hospital Universiti Sains Malaysia||Recruiting|
|Kota Bharu, Kelanatan, Malaysia, 16150|
|Contact: Dr W. Yus Haniff W. Isa 60199228373|